Income Tax - Deferred Tax Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating losses	$ 28,914,050	$ 24,542,949
R&D credits	3,830,306	3,822,392
Stock compensation	2,799,908	2,974,242
Lease liability	2,951,877
Deferred revenue	6,307	7,465
Section 174 costs	7,481,832	4,041,814
Other	319,826
Unrealized gains/losses	507,547	583,683
Deferred tax assets	46,811,653	35,972,545
Deferred tax liabilities:
Property, plant and equipment, primarily due to differences in depreciation	(738,290)	(553,840)
Lease liability	(5,573,944)	(2,732,712)
Other		(99,272)
Deferred tax liabilities	(6,312,234)	(3,385,824)
Valuation allowance	(40,499,419)	$ (32,586,721)
Change in gross unrecognized tax positions
Gross increases for tax positions related to the acquisition of Elusys Therapeutics	1,480,974,000
Divestiture of equity interests in Elusys Therapeutics	$ (1,480,974,000)